Engineered T-cell therapy across haematologic and solid tumours: target selection, dose and cytokine engineering, response durability, and the toxicity trade-offs that decide whether a construct reaches the clinic.
Single-center, nonrandomized Phase 1 dose-exploration trial of META 10-19 — a CD19 CAR T-cell product engineered to also express interleukin-10 — delivered at ultralow cell doses to 13 heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Open-label, single-center phase I dose-escalation and dose-expansion trial of IM96, an autologous GUCY2C-targeted CAR T-cell product, in 20 treated patients with microsatellite-stable, third- or later-line metastatic colorectal cancer — a population with very few remaining options